Investigational drug · Phase 2
Efinopegdutide
Also called: MK-6024, HM12525A, JNJ-64565111
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
6
Any phase or sponsor naming "Efinopegdutide"
First trial start
2023
Jun 23, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Efinopegdutide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-alcoholic Fatty Liver Disease
- Nonalcoholic Fatty Liver Disease
- Fatty Liver, Nonalcoholic
- NAFLD
- Nonalcoholic Steatohepatitis
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Liver Disease
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Efinopegdutide" as an intervention, largest first.
- A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05877547 · 381 participants · Start Jun 23, 2023 · Primary completion Dec 29, 2025
Drug: Efinopegdutide; Semaglutide and 1 more · For: Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD and 2 more
Sites: Chandler, Arizona; Peoria, Arizona; Tucson, Arizona · 175 sites in all
- A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04944992 · 145 participants · Start Aug 4, 2021 · Primary completion Oct 19, 2022
Drug: Efinopegdutide 20 mg/mL; Semaglutide 1.34 mg/mL · For: Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis
Sites: Montclair, California; Hialeah, Florida; Miami Lakes, Florida · 69 sites in all
- Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06482112 · 124 participants · Start Jul 29, 2024 · Primary completion Jun 27, 2025
Drug: Efinopegdutide · For: Metabolic Dysfunction-Associated Steatotic Liver Disease; Non-alcoholic Fatty Liver Disease; Nonalcoholic Fatty Liver Disease and 1 more
Sites: Chandler, Arizona; Peoria, Arizona; Tucson, Arizona · 39 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06836037 · 56 participants · Start Sep 5, 2022 · Primary completion Feb 2, 2023
Drug: Efinopegdutide; Placebo · For: Healthy
Sites: Shanghai, China
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06701305 · 48 participants · Start Jun 13, 2024 · Primary completion Feb 18, 2025
Drug: Efinopegdutide; Placebo and 1 more · For: Healthy
Sites: South Miami, Florida
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06052566 · 22 participants · Start Nov 21, 2023 · Primary completion Dec 5, 2024
Drug: Efinopegdutide · For: Non-alcoholic Steatohepatitis; Hepatic Impairment
Sites: Miami, Florida; Tampa, Florida; San Antonio, Texas · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Amjad MM, Khan MM, Sarwar F, et al. · Diabetes Obes Metab 2026
- Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study.
Lawitz E, Wong VW, Shankar RR, et al. · Lancet 2026
- Efinopegdutide: a step towards precision in MASH therapy?
Sookoian S, Pirola CJ · Lancet 2026
- Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
Moiz A, Filion KB, Samuels AE, et al. · Ann Intern Med 2026
- Future GLP-1 receptor co-agonists and their cardiac effects.
Neumann J, Kirchefer U, Hofmann B, et al. · Naunyn Schmiedebergs Arch Pharmacol 2026
- Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.
Gupta M, Shukla J · Indian J Med Res 2026
Also in development for Non-alcoholic Fatty Liver Disease
- EfimosferminBOS-580Phase 37 trials
GSK · Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic
- GSK4532990Phase 23 trials
GSK · Non-alcoholic Fatty Liver Disease, Liver Diseases, Alcoholic, Nonalcoholic Fatty Liver Disease
- HU6Phase 22 trials
Rivus Pharmaceuticals, Inc. · Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
- MN-001Phase 21 trial
MediciNova · Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.